BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hemophilia Alliance
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20230713T140000
DTEND;TZID=America/New_York:20230713T150000
DTSTAMP:20260406T113716
CREATED:20230706T203149Z
LAST-MODIFIED:20230713T131312Z
UID:44259-1689256800-1689260400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Presents - Gene Therapy Update
DESCRIPTION:Date: Thursday\, July 13\, 2023\nTime: 2:00pm – 3:00pm ET \n \nTOPIC:\nGene Therapy Update \nOBJECTIVES: \n\nReview the status of Roctavian and Hemgenix\, gene therapy products and the Alliance contracts with the Biomarin and CSL.\nProvide information on how to obtain the products and ensure they are infusion ready.\nExamine the rationale behind Biomarin’s decision to use Specialty Pharmacies and TAP for distribution and discuss how using TAP would benefit Hemophilia Treatment Centers (HTCs).\nConduct a comprehensive review of the Alliance Contract with CSL and Biomarin.\nCompare and analyze the pricing model and rebate program offered by Biomarin and CSL\, specifically in relation to gene therapy products.\n\nWe encourage you to submit questions ahead of time you would like to be answered or are just curious about. \nSPEAKER:\n\nJoe Pugliese\, President & CEO Hemophilia Alliance
URL:https://hemoalliance.org/alliance-events/member-webinar-hemophilia-alliance-presents-gene-therapy-update/
CATEGORIES:Members Only,Webinar
END:VEVENT
END:VCALENDAR